Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $12.85 USD
Change Today -0.02 / -0.16%
Volume 332.7K
INFI On Other Exchanges
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

infinity pharmaceuticals inc (INFI) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/12/14 - $18.25
52 Week Low
08/1/14 - $8.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

infinity pharmaceuticals inc (INFI) Related Businessweek News

No Related Businessweek News Found

infinity pharmaceuticals inc (INFI) Details

Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. The company is developing DYNAMO, which is in Phase II study to evaluate the safety and efficacy of IPI-145 dosed at 25 mg; DYNAMO+R that is in Phase III randomized study to evaluate IPI-145 dosed at 25 mg in combination with rituximab, a monoclonal antibody treatment; and DUO, which is in randomized Phase III monotherapy study evaluating IPI-145 dosed at 25 mg in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). It is also conducting a Phase Ib trial of IPI-145 in combination with obinutuzumab, a monoclonal antibody treatment in CLL patients; a Phase Ib/II clinical study of IPI-145 in combination with obinutuzumab or rituximab in patients with untreated follicular lymphoma; and an ongoing Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and clinical activity of IPI-145 in patients with advanced hematologic malignancies. The company has collaboration and license agreement with AbbVie Inc. to develop and commercialize IPI-145 in oncology; and development and license agreement with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

195 Employees
Last Reported Date: 02/24/15

infinity pharmaceuticals inc (INFI) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $568.5K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $390.0K
President of Research & Development
Total Annual Compensation: $479.5K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $647.1K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $381.0K
Compensation as of Fiscal Year 2014.

infinity pharmaceuticals inc (INFI) Key Developments

Infinity Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Infinity Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, net loss was $93.3 million, or a basic and diluted loss per common share of $1.91, compared to $42.3 million, or a basic and diluted loss per common share of $0.87, for the same period in 2014. Revenue during the first quarter of 2015 was $4.4 million for research and development services associated with the strategic collaboration with AbbVie for duvelisib in oncology. The company did not record any revenue in the first quarter of 2014. Collaboration revenue was $4,363,000. Loss from operations was $92,615,000 against $41,295,000 a year ago.

Infinity Pharmaceuticals Files Shelf Registration; Mulls Acquisitions

Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI) has filed a Shelf Registration. The net proceeds from the sale of any securities offered under this prospectus will be used for general corporate purposes unless otherwise indicated in the applicable prospectus supplement. General corporate purposes may include working capital and capital expenditures, research and development expenses, including clinical trial costs, general and administrative expenses, potential acquisition of, or investment in, companies, technologies, products or assets that complement our business, and repayment and refinancing of debt.

Infinity Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 05:00 PM

Infinity Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 05:00 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Adelene Q. Perkins, Chairman of The Board, Chief Executive Officer and President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INFI:US $12.85 USD -0.02

INFI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $1.71 USD -0.03
Cytokinetics Inc $6.22 USD -0.05
Evotec AG €4.00 EUR -0.098
Exelixis Inc $3.15 USD +0.01
GlaxoSmithKline SAE £11.52 EGP 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation INFI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.7x
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INFINITY PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at